Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips. The cuts will go into effect by Oct. 2, according to a Worker Adjustment and Retraining Notification (WARN) Act filing with the Garden State.
Novartis is making changes to its field sales, patient support and marketing organizations to “enhance operational efficiency and ensure we are investing resources where they can have the greatest impact," a company spokesperson wrote in an emailed statement. "As a result, some roles are impacted."
“Novartis continually evaluates opportunities to align our organization with evolving patient, customer and business needs,” the spokesperson added.
It is the fourth round of dismissals over the last five months at the East Hanover site. The other three rounds of cuts, which also were listed in WARN reports, will cost a total of 250 employees their jobs.
In March, Novartis moved to eliminate 114 roles at its U.S. home base and explained that it was reworking its sales team for rare disease medicines, including chronic myeloid leukemia treatment Tasigna and platelet-stimulating agent Promacta, both of which are losing patent protection this year.
Two months later in May, Novartis said it would chop another 76 positions, with the company citing a downsizing of its biomedical research arm. A few weeks after that, the company telegraphed an additional 60 job cuts, saying that it had “taken steps to evolve our Oncology, Rheumatology, Dermatology and Neuroscience field sales teams in the U.S."
Novartis is feeling the pinch of the loss of exclusivity (LOE) of megablockbuster heart failure medicine Entresto, which began in July of last year. Revenue from the heart failure medicine plummeted from $2.3 billion in the first quarter of 2025 to $1.3 billion in this year’s first quarter. With the dropoff, Novartis saw its overall sales decline in the first quarter by 1%, this coming after the company reported revenue increases of 12% in 2024 and 8% in 2025.
In March of 2025, Novartis also slashed 427 jobs, citing the oncoming LOE of Entresto.
Novartis has been working to adjust and right-size its operations since 2022, when it merged its oncology and pharmaceuticals units into one innovative medicines business that is now managed by geographic locations.